2. Anti-infection PI3K/Akt/mTOR Membrane Transporter/Ion Channel Immunology/Inflammation NF-κB Metabolic Enzyme/Protease
  3. HIV PIN1 Fungal GLUT Reactive Oxygen Species (ROS)
  4. Zingibroside R1

Zingibroside R1 is an orally active triterpene saponin with multiple biological activities including antioxidant, anti-inflammatory, antiviral, and metabolic regulatory properties. Zingibroside R1 reduces the expression of PIN family members, inhibits the expression of PLT1/PLT2, WOX5, SHR, and SCR, disrupts auxin transport and distribution, triggers plant ROS responses, and inhibits root growth. Zingibroside R1 extends the lifespan of Caenorhabditis elegans, enhances its heat stress resistance, and improves its motor ability. Hydrogel derivatives of Zingibroside R1 inhibit the proliferation of Candida albicans by binding to its β-1,3-glucan and exhibit antifungal activity. Zingibroside R1 inhibits GLUT1-mediated uptake and alleviates liver injury. Zingibroside R1 can be used in research related to neurodegenerative diseases, vulvovaginal candidiasis, acute liver injury, Ehrlich ascites tumor and HIV-1 infection.

For research use only. We do not sell to patients.

Zingibroside R1

Zingibroside R1 Chemical Structure

CAS No. : 80930-74-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Zingibroside R1 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Zingibroside R1

View All HIV Isoform Specific Products:

View All Isoforms
HIV HIV-1 HIV-2

View All GLUT Isoform Specific Products:

View All Isoforms
GLUT1 GLUT2 GLUT3 GLUT4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Zingibroside R1 is an orally active triterpene saponin with multiple biological activities including antioxidant, anti-inflammatory, antiviral, and metabolic regulatory properties. Zingibroside R1 reduces the expression of PIN family members, inhibits the expression of PLT1/PLT2, WOX5, SHR, and SCR, disrupts auxin transport and distribution, triggers plant ROS responses, and inhibits root growth. Zingibroside R1 extends the lifespan of Caenorhabditis elegans, enhances its heat stress resistance, and improves its motor ability. Hydrogel derivatives of Zingibroside R1 inhibit the proliferation of Candida albicans by binding to its β-1,3-glucan and exhibit antifungal activity. Zingibroside R1 inhibits GLUT1-mediated uptake and alleviates liver injury. Zingibroside R1 can be used in research related to neurodegenerative diseases, vulvovaginal candidiasis, acute liver injury, Ehrlich ascites tumor and HIV-1 infection[1][2][3][4][5].

IC50 & Target[5]

HIV-1

 

GLUT1

 

In Vitro

Zingibroside R1 (ZR1) (20-100 μM; 15-45 days) dose-dependently inhibits the adventitious root density and root apical meristem length of ginseng adventitious roots[1].
Zingibroside R1 (5-10 μM; 2-7 days) dose-dependently inhibits primary root elongation, meristematic zone length, and elongation zone length in Arabidopsis thaliana Col-0 seedlings[1].
Zingibroside R1 (5-10 μM; 2-7 days) reduces endogenous IAA levels in Arabidopsis thaliana and disrupts its polar auxin transport by decreasing the fluorescence intensity of specific PIN transporter markers[1].
Zingibroside R1 (5-10 μM; 2-4 days) regulates the expression of core root stem cell regulators in Arabidopsis thaliana[1].
Zingibroside R1 (5-10 μM; 7-10 days) induces oxidative stress in Arabidopsis thaliana Col-0 seedlings by promoting ROS accumulation, impairing the activity of ROS-scavenging enzymes, and altering the GSH/GSSG redox balance[1].
Zingibroside R1 (2.0 wt%; 1 h heating, 30 min cooling, 6-24 h cell incubation) forms a stable hydrogel with shear recovery property, and exhibits excellent biocompatibility with human Caco-2 cells[3].
Hydrogel containing 2.0 wt% Zingibroside R1 (ZR1), upon incubation for 2-24 h, potently inhibits the proliferation of Candida albicans in vitro by disrupting cell membrane integrity[3].
Nanofibrils of Zingibroside R1 (100 ns simulation) exhibit high binding affinity for β-1,3-glucan in the cell wall of Candida albicans, and disrupt the integrity of fungal cell membranes through hydrogen bonding and structural perturbation[3].
Zingibroside R1 (2.0 wt%; 24 h incubation) hydrogel can stably encapsulate Lactobacillus rhamnosus GG and achieve sustained release, while the LGG@ZR1 formulation exerts synergistic inhibitory effects on the proliferation of Candida albicans in vitro and acidifies the culture medium[3].
Zingibroside R1 (compound 13) (10-100 μM; 10 min preincubation, 1 min uptake measurement) inhibits the uptake of 2-deoxyglucose (2-DG) by Ehrlich ascites tumor (EAT) cells, with an IC50 of 91.3 μM, and acts as a partial competitive inhibitor of glucose transport[5].
Zingibroside R1 (5 days) exhibits cytotoxicity (CC50 = 46.2 μM) and anti-HIV-1 activity against the human T-cell line (MT-4)[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zingibroside R1 Related Antibodies
In Vivo

Zingibroside R1 (4 µg/mL; incorporated into NGM agar plates and OP50 bacteria; continuous exposure from L4 larval stage through adulthood) extends the mean lifespan of N2 C. elegans by 10%, increases mean survival after heat stress by 12.1%, and improves multiple parameters of swimming behavior in aged nematodes[2].
Zingibroside R1 (2% w/v; i.vag.; daily; 9 days) gel exhibits in vivo efficacy against vulvovaginal candidiasis in BALB/c mice, reducing fungal burden and vaginal inflammation[3].
Zingibroside R1 (R1) (15-30 mg/kg; p.o.; daily; 7 days) exerts significant hepatoprotective effects against LPS/D-GalN-induced acute liver injury in male BALB/c mice by reducing oxidative stress, suppressing inflammation, modulating immune cell populations, restoring gut microbiota balance, and regulating hepatic metabolite profiles including succinic acid[4].
Zingibroside R1 (30 mg/kg; oral; once daily; for 7 days) fecal microbiota transplantation in mice significantly ameliorates LPS/D-GalN-induced acute liver injury in male BALB/c mice by attenuating oxidative stress, inhibiting inflammatory responses, and restoring the hepatic metabolite profile including succinate[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 18-20 g, vulvovaginal candidiasis model induced by subcutaneous estradiol benzoate followed by intravaginal C. albicans inoculation)[3]
Dosage: 2% w/v
Administration: i.vag.; daily; 9 days
Result: Reduced C. albicans colony counts from vaginal washes throughout the treatment period.
Lessened epithelial disruption and neutrophil infiltration in vaginal tissues compared to untreated controls.
Showed gradual improvement in vaginal redness and inflammation by day 9.
Revealed residual fungal presence in vaginal tissues via PAS staining.
Animal Model: BALB/c (male, 18-22 g, LPS/D-GalN-induced acute liver injury)[4]
Dosage: 15 mg/kg; 30 mg/kg
Administration: p.o.; daily; 7 days
Result: Showed significant reduction in liver haemorrhaging, hepatocyte necrosis, nuclear shrinkage and inflammatory infiltration.
Decreased serum ALT and AST levels.
Reduced hepatic and serum ROS and MDA levels, and increased serum and hepatic SOD and GSH-Px activities.
Reduced hepatocyte apoptosis rate.
Decreased hepatic levels of TNF-α, IL-1β, IL-6 and IFN-γ, and increased IL-2 level.
Upregulated hepatic and peripheral blood Th cells, Tc cells, DCs and NK cells, and downregulated Tregs, macrophages (F4/80) and neutrophils (LY-6G).
Restored Shannon and Simpson indices, increased relative abundance of Ligilactobacillus, and decreased relative abundances of Clostridium and Anaerotignum.
Normalized liver metabolic profile, increased taurine, allose, L-carnitine, hypoxanthine, glycerol and 4-trimethylammoniobutanoic acid, and decreased succinic acid and D-lysine.
Animal Model: BALB/c (male, 18-22 g, LPS/D-GalN-induced acute liver injury with faecal microbiota transplantation)[4]
Dosage: Faecal microbiota from mice treated with 30 mg/kg Zingibroside R1
Administration: p.o.; daily; 6 days
Result: Showed reduced hepatocyte necrosis, nuclear shrinkage and inflammatory cell infiltration compared to the M-FMT group.
Decreased serum ALT and AST levels relative to the M-FMT group.
Reduced hepatic ROS generation rate and hepatocyte apoptosis rate compared to the M-FMT group.
Normalized the liver metabolic profile, increased hypoxanthine and glycerophosphocholine, and decreased succinic acid relative to the M-FMT group.
Decreased hepatic levels of pro-inflammatory cytokines IL-1β, TNF-α, IL-6 and IFN-γ compared to the M-FMT group.
Molecular Weight

794.97

Formula

C42H66O14
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12C([C@@]3([H])[C@](C(O)=O)(CCC(C)(C)C3)CC2)=CC[C@]4([H])[C@@](C)(CC[C@H](O[C@@]5([H])[C@@H]([C@H]([C@H](O)[C@@H](C(O)=O)O5)O)O[C@]6([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)CO)C7(C)C)[C@@]7([H])CC[C@@]14C
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (125.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.2579 mL 6.2895 mL 12.5791 mL
5 mM 0.2516 mL 1.2579 mL 2.5158 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.75%

SDS (252 KB)

COA (257 KB) HNMR (331 KB) LCMS (92 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.2579 mL 6.2895 mL 12.5791 mL 31.4477 mL
5 mM 0.2516 mL 1.2579 mL 2.5158 mL 6.2895 mL
10 mM 0.1258 mL 0.6290 mL 1.2579 mL 3.1448 mL
15 mM 0.0839 mL 0.4193 mL 0.8386 mL 2.0965 mL
20 mM 0.0629 mL 0.3145 mL 0.6290 mL 1.5724 mL
25 mM 0.0503 mL 0.2516 mL 0.5032 mL 1.2579 mL
30 mM 0.0419 mL 0.2097 mL 0.4193 mL 1.0483 mL
40 mM 0.0314 mL 0.1572 mL 0.3145 mL 0.7862 mL
50 mM 0.0252 mL 0.1258 mL 0.2516 mL 0.6290 mL
60 mM 0.0210 mL 0.1048 mL 0.2097 mL 0.5241 mL
80 mM 0.0157 mL 0.0786 mL 0.1572 mL 0.3931 mL
100 mM 0.0126 mL 0.0629 mL 0.1258 mL 0.3145 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Zingibroside R1 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zingibroside R180930-74-1Zingibroside R 1Zingibroside R-1HIVPIN1FungalGLUTReactive Oxygen Species (ROS)Human immunodeficiency viruspeptidylprolyl cis/trans isomerase, NIMA-interacting 1Glucose transporterPIN transporterCandida albicansPanax ginsengβ-1,3-glucanArabidopsis thalianaBALB/c miceMT-4 cellsCaenorhabditis elegansCaco-2 cellsEhrlich ascites tumor cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Zingibroside R1
Cat. No.:
HY-N6924
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.